Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This presentation reviews the role and implementation of journal clubs in physical medicine and rehabilitation but reports no new research findings.

This article reports no new findings as it lacks an abstract.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

In this case study, ischemic stroke occurred in a 20-year-old male taking finasteride for hair loss, with multiple genetic predispositions for thrombosis; while causality is uncertain, clinicians should exercise caution when prescribing finasteride to patients with thrombotic risk factors.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review found that hormones significantly impact women's health and athletic performance, influencing the menstrual cycle, menopause, and exercise responses, while therapies like contraception and hormone replacement require personalized approaches to balance benefits and risks.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that cyclosporine-A might significantly increase the risk of cerebral venous and arterial thrombosis in patients with aplastic anemia.

This review discusses the impact of gender affirming hormone therapy on cardiovascular outcomes in transgender individuals and reports no new clinical results; the authors underscore the need for more comprehensive studies.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This study highlights the severe health risks and dependence associated with non-medical androgen use among gym-goers, stressing the need for specialized primary care and harm-reduction strategies due to potentially fatal outcomes even after prolonged cessation.

This article reviews treatment approaches for polycystic ovary syndrome, highlighting lifestyle changes, medications like metformin for insulin resistance, and fertility therapies, acknowledging the complexities and contraindications involved.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

CTP-543 is generally safe for treating alopecia areata.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study found that hormone replacement therapy was associated with reduced COVID-19 mortality and adverse outcomes in nonimmunosuppressed postmenopausal women and immunocompromised male solid organ transplant recipients.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.